NF-κB regulates the expression of STING via alternative promoter usage

Lin-Yuan Chen,Xiao-Yu Pang,Can Chen,Hua-Guo Xu

DOI: https://doi.org/10.1016/j.lfs.2022.121336

IF: 6.78

2023-02-01

Life Sciences

Abstract:AIMS: Stimulator of interferon genes (STING) is a transmembrane protein in endoplasmic reticulum and plays crucial roles in autophagy, antiviral and anti-tumor responses. However, there are few studies on the transcriptional regulation mechanism of STING.MAIN METHODS: The 5' RACE experiment was used to determine the location of STING promoters. Luciferase reporting assay confirmed the activity and core region of STING internal promoter. Site-directed mutagenesis confirmed that NF-κB regulates the activity of STING promoters. The regulation of NF-κB on STING was investigated by real-time quantitative PCR, western blot, chromatin immunoprecipitation assay and lipopolysaccharide (LPS) inflammatory cell model.KEY FINDINGS: There was also a transcription start site at the 17 bp sequence upstream of STING second exon. STING-285 was the core region of the internal promoter. After NF-κB binding site mutation, the activity of STING internal promoter decreased significantly. In addition, we found that NF-κB can bind to the promoter region of wild-type STING. Overexpression of NF-κB significantly increased the activity of STING internal promoter and wild-type promoter, while knockdown of endogenous NF-κB significantly inhibited the activity of STING promoters. The binding of NF-κB to STING promoters in vivo were confirmed by chromatin immunoprecipitation assay. Meanwhile, we stimulated HeLa cells with LPS to activate the NF-κB pathway and found that STING expression was up-regulated.SIGNIFICANCE: These results suggest that transcription factor NF-κB positively regulates the expression of STING via alternative promoter usage. This provides a new basis and potential drug targets for the clinical treatment of STING related diseases.

pharmacology & pharmacy,medicine, research & experimental